Comparison of Test Statistics for the Sequential Parallel Design
Authors:
- Xiaohong HuangXHXiaohong Huang
- Roy N. TamuraRTRoy N. Tamura
- 1 February 2010
- journal article
- Published by Taylor & Francis in Statistics in Biopharmaceutical Research
- Vol. 2 (1) , 42-50
Abstract
The sequential parallel design has been proposed to improve the efficiency of clinical trials in psychiatry. The design randomizes patients into three treatment groups. Each group has two phases. The three groups are (1) placebo in the first phase followed by placebo in the second phase, (2) placebo in the first phase followed by drug in the second phase, and (3) drug in the first phase followed by drug in the second phase. We consider the case of binary response data. The analysis of data in the second phase of the trial is restricted to placebo patients who failed to respond in the first phase of the trial. A crucial element in the choice of test statistics is the underlying assumptions of treatment effect in the two phases of the trial. We develop various likelihood-based statistics when the treatment effect is different in the two phases and for the special case in which the treatment effect is equal in the two phases. These statistics are compared in simulation studies to determine their underlying null and nonnull behavior. The score test under the assumption of equal treatment effects is seen to have advantages in terms of Type I error and robustness to assumptions.Keywords
This publication has 7 references indexed in Scilit:
- Enrichment Design2007
- An examination of the efficiency of the sequential parallel design in psychiatric clinical trialsClinical Trials, 2007
- ErratumPsychotherapy and Psychosomatics, 2004
- The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design ApproachPsychotherapy and Psychosomatics, 2003
- Frequency of Positive Studies Among Fixed and Flexible Dose Antidepressant Clinical Trials: An Analysis of the Food and Drug Administraton Summary Basis of Approval ReportsNeuropsychopharmacology, 2002
- Assay Sensitivity, Failed Clinical Trials, and the Conduct of SciencePsychotherapy and Psychosomatics, 2002
- Placebo Response in Studies of Major DepressionJAMA, 2002